ENvue Medical Inc. (FEED) AI Stock Analysis
FEED AI stock analysis summary
AI ResearchENvue Medical Inc. (FEED) is a medical devices company focused on non-invasive biological response-activating ultrasound technologies. In FY2025, revenue was $2.6M with a net loss of -$18.2M, while trailing twelve-month revenue stood at $1.9M with an operating margin of -2290.4%. The company held $1.1M in cash against $1.3M in total debt as of June 30, 2026, and its stock has dropped 99.5% over the past year.
- Market cap
- $342,699
- Revenue (TTM)
- $1.9M
- P/E
- —
- 1Y return
- -99.5% S&P 500 16.8%
- Avg. target
- —
Bull case
- Revenue expanded at a 5-year compound annual growth rate of 32.6% from FY2020 through FY2025.
- Company insiders maintain alignment with the business by holding 16.4% of outstanding shares.
- The balance sheet maintains a low debt-to-equity ratio of 0.04 with total debt of $1.3M as of June 30, 2026.
Bear case
- Net losses deepened significantly in FY2025 to -$18.2M from -$3.7M in FY2024 as free cash flow reached -$9.4M.
- Gross margin deteriorated sharply from 59.0% in FY2024 to 6.0% in FY2025.
- The stock has lost 99.5% of its value over the trailing 12 months, trading 97.3% below its 200-day moving average.
What ENvue Medical does
ENvue Medical, Inc., formerly known as NanoVibronix, Inc., focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at-home administration without medical professional assistance. Its product portfolio includes UroShield and UroShield Ultra, which use ultrasound to prevent bacterial colonization and biofilm in urinary catheters. The company also offers PainShield, PainShield MD, and PainShield Plus, which utilize patch-based therapeutic ultrasound technology to treat pain, muscle spasms, and joint contractures. In addition, it provides WoundShield to aid tissue regeneration and wound healing. Products are sold directly to patients and through distributor agreements globally.
Growth and profitability
Between FY2021 and FY2025, ENvue Medical's revenue grew at a 5-year CAGR of 32.6%, moving from $1.7M in FY2021 to $2.6M in FY2025. Annual revenue was $752,000 in FY2022, $2.3M in FY2023, and $2.6M in FY2024. Profitability remains challenged as gross margin fell from 67.3% in FY2023 and 59.0% in FY2024 to 6.0% in FY2025. Operating margin was -459.7% in FY2025, down from -140.0% in FY2024. Net income worsened to -$18.2M in FY2025 compared to -$3.7M in FY2024. For the latest quarter ended June 30, 2026, quarterly revenue fell 51.6% year-over-year, bringing trailing twelve-month revenue to $1.9M.
Balance sheet and cash flow
As of June 30, 2026, ENvue Medical held $1.1M in cash and short-term investments against $1.3M in total debt, resulting in net debt of $169,000. Total assets stood at $38.4M alongside shareholders' equity of $30.8M, leading to a debt-to-equity ratio of 0.04 and a current ratio of 0.66. FY2025 operating cash flow was -$9.4M, matching free cash flow of -$9.4M. During FY2025, the company used $60,000 for capital expenditures and allocated $5.0M to share buybacks.
Valuation and performance
ENvue Medical carries a market cap of $342,699 and an enterprise value of $734,044. Its price-to-sales ratio of 0.2x and EV-to-revenue ratio of 0.4x trade below the median of its US-listed Healthcare peers, which post a median price-to-sales ratio of 4.1x and EV-to-EBITDA of 12.0x. ENvue Medical's EV-to-EBITDA stands at 0.4x, with a price-to-book ratio of 0.0x. Over the past year, FEED shares fell 99.5%, while the S&P 500 (SPY) returned 16.8%. Over five years, the stock dropped 100.0% compared to an 83.0% gain for SPY.
What analysts expect
There are no analyst ratings, target prices, or earnings projections reported for ENvue Medical Inc. following its close at $0.37 on October 16, 2026. The company, which has a market cap of $342,699 and an enterprise value of $734,044, lacks published Wall Street coverage or future consensus estimates. In addition, the company has no scheduled next earnings date listed. Because of this absence of institutional research coverage, historical earnings surprises and future financial guidance benchmarks remain unavailable for FEED.
Key risks and what to watch
- A current ratio of 0.66 as of June 30, 2026 indicates working capital pressure relative to short-term obligations.
- A trailing twelve-month operating margin of -2290.4% highlights extreme ongoing operational losses.
- Revenue declined 51.6% year-over-year in the quarter ended June 30, 2026, signaling contracting topline momentum.
- Cash and short-term investments stood at $1.1M as of June 30, 2026, which is small relative to the FY2025 operating cash outflow of -$9.4M.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this FEED AI stock analysis
This page is an AI-written research summary of ENvue Medical Inc. (FEED). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: FEED income statement, FEED balance sheet, FEED key metrics, FEED chart. See the FEED stock overview for the latest quote and news.
FEED AI stock analysis FAQ
What was ENvue Medical's revenue in FY2025?
ENvue Medical reported revenue of $2.6M in FY2025, down 0.2% compared to FY2024. Trailing twelve-month revenue as of June 30, 2026 was $1.9M.
Does ENvue Medical pay a dividend?
ENvue Medical does not pay a dividend. In FY2025, the company deployed $5.0M toward share buybacks and $60,000 toward capital expenditures.
What is ENvue Medical's cash and debt position?
As of June 30, 2026, ENvue Medical had $1.1M in cash and short-term investments and $1.3M in total debt. This resulted in net debt of $169,000 and a debt-to-equity ratio of 0.04.
How has FEED stock performed over the past year?
FEED shares fell 99.5% over the past year as of October 16, 2026, closing at $0.37. Over the same period, the S&P 500 (SPY) gained 16.8%.
Why was the company previously called NanoVibronix?
The company was incorporated in 2003 as NanoVibronix, Inc. and officially changed its name to ENvue Medical, Inc. in December 2025.